

**REMARKS**

Applicants respectfully request entry of the foregoing preliminary amendment to facilitate prosecution of the application. The amendments are supported by the specification. Thus, the amendment of claims 1 and 16 is found in the specification at pages 26-28 and Figures 5-8 describing detection of IDO+ APCs in tumors that express mip-3 $\alpha$ , and the use of antibodies to CCR6 to reduce migration of IDO+ cells that express CCR6 to mip-3 $\alpha$ . Also, new claim 47 finds support in the specification at page 17, line 29 to page 18, line 2, and page 18, lines 26 –31, and Figure 1 and the related text at page 21, line 17 to page 22, line 31, describing dendritic cells that function as APCs or the precursors of APCs. Other amendments are made to improve the syntax of the claims. Accordingly no new matter is added by the amendment of the claims.

**CONCLUSION**

In view of the foregoing amendment and remarks, each of the claims remaining in the application is in condition for immediate allowance. Accordingly, the Examiner is respectfully requested to reconsider and withdraw the outstanding rejections. The Examiner is respectfully invited to telephone the undersigned at (336) 747-7541 to discuss any questions relating to the application.

Respectfully submitted,

Date: June 13, 2006

  
Cynthia B. Rothschild (Reg. No. 47,040)

KILPATRICK STOCKTON LLP  
1001 West Fourth Street  
Winston-Salem, North Carolina 27101-2400  
Phone: (336) 747-7541  
Facsimile: (336) 607-7500